BALTIMORE, Sept. 14, 2020 /PRNewswire/ — GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.daiichisankyo.com). The agreement grants Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB and UMCP, and includes an undisclosed upfront payment, annual fees, and adequate royalties of sales to GlycoT.
{iframe}https://curated.tncontentexchange.com/states/maryland/glycot-therapeutics-grants-sublicense-of-glycoengineering-technology-to-daiichi-sankyo/article_45bf34e7-1b9b-59b5-a44d-fe37dd91d402.html{/iframe}